Area of research
Hematology · Pathology and Forensic Medicine
Research interest
Research interests include Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia Research, Lymphoma Diagnosis and Treatment, and Acute Lymphoblastic Leukemia research.
Circulating Neoantigen- and Viral Oncoprotein-Specific CD8+ T Cells Share a Transcriptional Signature.
Figure S1 from Circulating Neoantigen- and Viral Oncoprotein–Specific CD8<sup>+</sup> T Cells Share a Transcriptional Signature
Tooth Loss and Oral Health-related Quality of Life in a Sub-cohort Within the Chronic Graft-Versus-Host Disease Consortium
Figure S6 from Circulating Neoantigen- and Viral Oncoprotein–Specific CD8<sup>+</sup> T Cells Share a Transcriptional Signature
Supplementary Tables from Circulating Neoantigen- and Viral Oncoprotein–Specific CD8<sup>+</sup> T Cells Share a Transcriptional Signature
Figure S4 from Circulating Neoantigen- and Viral Oncoprotein–Specific CD8<sup>+</sup> T Cells Share a Transcriptional Signature
Data from Circulating Neoantigen- and Viral Oncoprotein–Specific CD8<sup>+</sup> T Cells Share a Transcriptional Signature
Figure S5 from Circulating Neoantigen- and Viral Oncoprotein–Specific CD8<sup>+</sup> T Cells Share a Transcriptional Signature
Figure S2 from Circulating Neoantigen- and Viral Oncoprotein–Specific CD8<sup>+</sup> T Cells Share a Transcriptional Signature
Figure S3 from Circulating Neoantigen- and Viral Oncoprotein–Specific CD8<sup>+</sup> T Cells Share a Transcriptional Signature
Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma
Social determinants of health and access to allogeneic hematopoietic cell transplantation for acute myeloid leukemia
RGI-2001 for the prophylaxis of acute graft-versus-host disease after allogeneic HCT.
Pretargeted Anti-CD20 Radioimmunotherapy with scFv Fusion Protein Safely Combines with BEAM and ASCT in Patients with High-risk B-cell Lymphomas.
Supplementary Fig. 1 from Pretargeted Anti-CD20 Radioimmunotherapy with scFv Fusion Protein Safely Combines with BEAM and ASCT in Patients with High-risk B-cell Lymphomas
HRDetect in Ovarian Carcinoma: Stratification and Therapeutic Implications
Supplementary Table 1 from Pretargeted Anti-CD20 Radioimmunotherapy with scFv Fusion Protein Safely Combines with BEAM and ASCT in Patients with High-risk B-cell Lymphomas
Data from Pretargeted Anti-CD20 Radioimmunotherapy with scFv Fusion Protein Safely Combines with BEAM and ASCT in Patients with High-risk B-cell Lymphomas
Supplementary Fig. 2 from Pretargeted Anti-CD20 Radioimmunotherapy with scFv Fusion Protein Safely Combines with BEAM and ASCT in Patients with High-risk B-cell Lymphomas
HRDetect in Ovarian Carcinoma: Stratification and Therapeutic Implications
Targeted Radiation Delivery before Haploidentical HCT for High-risk Leukemia or MDS Patients Yields Long-term Survivors.
AML-591 Barriers to Receiving Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Insights From a Large-Scale Multicenter Observational Study
Barriers to Receiving Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Insights From a Large-Scale Multicenter Observational Study
Supplementary Table S1 from Targeted Radiation Delivery before Haploidentical HCT for High-risk Leukemia or MDS Patients Yields Long-term Survivors
Supplementary Fig S2 from Targeted Radiation Delivery before Haploidentical HCT for High-risk Leukemia or MDS Patients Yields Long-term Survivors
Supplementary Fig S1 from Targeted Radiation Delivery before Haploidentical HCT for High-risk Leukemia or MDS Patients Yields Long-term Survivors
Supplementary Table S1 from Targeted Radiation Delivery before Haploidentical HCT for High-risk Leukemia or MDS Patients Yields Long-term Survivors
Supplementary Fig S1 from Targeted Radiation Delivery before Haploidentical HCT for High-risk Leukemia or MDS Patients Yields Long-term Survivors
Supplementary Fig S2 from Targeted Radiation Delivery before Haploidentical HCT for High-risk Leukemia or MDS Patients Yields Long-term Survivors
Data from Targeted Radiation Delivery before Haploidentical HCT for High-risk Leukemia or MDS Patients Yields Long-term Survivors